Phase II Study of Gefitinib, an Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitor (EGFR-TKI), and Celecoxib, a Cyclooxygenase-2 (COX-2) Inhibitor, in Patients with Platinum Refractory Non-small Cell Lung Cancer (NSCLC)-Reference-Cited by-同舟云学术

Phase II Study of Gefitinib, an Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitor (EGFR-TKI), and Celecoxib, a Cyclooxygenase-2 (COX-2) Inhibitor, in Patients with Platinum Refractory Non-small Cell Lung Cancer (NSCLC)

Published:2007-04 Issue:4 Volume:2 Page:299-305
ISSN:1556-0864
Container-title:Journal of Thoracic Oncology
language:en
Short-container-title:Journal of Thoracic Oncology

Author:

Gadgeel Shirish M.,Ruckdeschel John C.,Heath Elisabeth I.,Heilbrun Lance K.,Venkatramanamoorthy Raghu,Wozniak Antoinette

Publisher

Elsevier BV

Subject

Pulmonary and Respiratory Medicine,Oncology

Reference56 articles.

1. Annual report to the nation on the status of cancer, 1975–2002, featuring population trends in cancer treatment;Edwards;J Natl Cancer Inst,2005

2. Comparison of four chemotherapy regimens for advanced non-small-cell lung cancer;Schiller;N Engl J Med,2002

3. Randomized phase III trial of pemetrexed versus docetaxel in patients with non-small-cell lung cancer previously treated with chemotherapy;Hanna;J Clin Oncol,2004

4. Erlotinib in previously treated non-small-cell lung cancer;Shepherd;N Engl J Med,2005

5. ErbB-targeted therapeutic approaches in human cancer;Arteaga;Exp Cell Res,2003

Cited by 53 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Crizotinib inhibits the metabolism of tramadol by non-competitive suppressing the activities of CYP2D1 and CYP3A2;PeerJ;2024-05-30

2. The use of non-steroid anti-inflammatory drugs during radical resection correlated with the outcome in non-small cell lung cancer;World Journal of Surgical Oncology;2023-11-21

3. Targeting cancer-related inflammation with non-steroidal anti-inflammatory drugs: Perspectives in pharmacogenomics;Frontiers in Pharmacology;2022-12-05

4. Circulating Tumour Cells (CTCs) in NSCLC: From Prognosis to Therapy Design;Pharmaceutics;2021-11-05

5. Tumor necrosis factor in lung cancer: Complex roles in biology and resistance to treatment;Neoplasia;2021-02